Morana Vojnic, MD, MBA, explains how FET-PET imaging's FDA approval is enabling neuro-oncologists to identify ...

Perioperative enfortumab vedotin plus pembrolizumab had a cost-effectiveness ratio of $72,460 per QALY vs radical cystectomy ...

Paul L. Swiecicki, MD, of the University of Michigan Rogel Cancer Center, discusses how Breakthrough Therapy Designation and ...

FDA final guidance sets a risk-based potency assurance roadmap for cell and gene therapies, spanning development, ...

SABR had higher 3-year all-cause mortality than surgery in early-stage NSCLC (30.3% vs 21.6%) in an emulated target trial; ...

Hoth Therapeutics stopped the phase 2a CLEER-001 trial of topical HT-001 early after an interim review and will seek FDA input on phase 3.

Updated ENZARAD findings show no significant metastasis-free survival benefit with enzalutamide, although patients receiving pelvic lymph node radiation may benefit from intensification.

Jacob Sands, MD, discusses the top findings from the phase 3 DeLLphi-305 study evaluating tarlatamab and durvalumab as ...

ADCs improved on chemotherapy-based regimens in PD-L1–negative and EGFR-mutated NSCLC, while chemotherapy plus pembrolizumab ...

Dirk Schadendorf, MD, discusses where triplet therapy fits for BRAF V600-mutant melanoma following the results of the STARBOARD trial.

Bhavana Pothuri, MD, discusses TroFuse-005 at ESMO 2026, including TROP2 expression, treatment sequencing, and the future of ...

The IMpactMF trial was discontinued after an independent committee determined imetelstat was unlikely to improve overall ...